Status:
COMPLETED
A Study to Evaluate P-Glucose, Safety and Tolerability After Oral Single Dosing of AZD6370 in Type 2 Diabetic Patients
Lead Sponsor:
AstraZeneca
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
30-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the effect of AZD6370 on blood sugar and to study safety and tolerability in patients with type 2 diabetes.
Eligibility Criteria
Inclusion
- Treated with diet or metformin. Stable glycemic control indicated by no changed treatment within 3 months
- Diabetes Mellitus diagnosis \<5 years
Exclusion
- Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two weeks before the first administration of the investigational product
- Clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00690287
Start Date
February 1 2008
End Date
June 1 2008
Last Update
January 11 2012
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Linköping, Sweden
2
Research Site
Luleå, Sweden
3
Research Site
Uppsala, Sweden